Pfizer and Rosa to present at 2012 Keystone Symposia: Pathogenesis of Diabetes

FOR IMMEDIATE RELEASE
San Carlos, California, United States of America (Free-Press-Release.com) January 25, 2012 --

1

Pfizer and Rosa to present at 2012 Keystone Symposia: Pathogenesis of Diabetes

Welcome visit Our WebSite:

http://www.rosaandco.com

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent collaborative research project with Pfizer will be presented at the 2012 Keystone Symposia: “Pathogenesis of Diabetes: Emerging Insights into Molecular Mechanisms” in Santa Fe, New Mexico on Monday, January 30, 2012. Dr. Rebecca Baillie will be presenting a poster entitled “Novel insights into the importance of insulin degradation in glucose metabolism”. The poster will describe the critical contribution of insulin degradation to patient variability in insulin and glucose homeostasis. This work will also highlight the use of a Diabetes PhysioPD™ model to gain additional insight from clinical data and to evaluate and test multiple hypotheses regarding insulin degradation.

“We are pleased to present results from this collaboration with Pfizer. This work is a demonstration of how modeling can be used to advance fundamental scientific understanding relevant to drug development, extract more value from clinical data, and systematically evaluate alternate biological hypotheses,” said Dr. Mike Reed, Rosa’s Vice President of Client Services.

About Rosa

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

More information can be found online at http://www.rosaandco.com

clinical trial analysis     diabetes     drug development model     insulin     pharmaceutical data integratio     physiological modeling and sim     PhysioPD     PhysioPD model